Back to News
Market Impact: 0.42
Zealand Pharma Gets Positive EU Opinion For Zeydovio In Short Bowel Syndrome
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Zealand Pharma's Zeydovio (glepaglutide) received a positive CHMP recommendation for European marketing authorization to treat adults with short bowel syndrome. The recommendation is a key regulatory milestone that supports potential EMA approval and commercial launch in the EU.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
ZEAL0.82
More News
- Apple's quarter is not perfect. But with enough to like, we raised our price target
- California’s Bay Area debates data centres ahead of US midterm elections
- ‘Fastest entertainment property in history’: GTA VI arrives to test a thin November box office
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- ‘Going hungry’: Garment workers in Bangladesh say wages barely cover needs